Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Down – Here’s Why

Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) gapped down before the market opened on Wednesday . The stock had previously closed at $12.57, but opened at $11.8390. Santen Pharmaceutical shares last traded at $11.8390, with a volume of 516 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, Santen Pharmaceutical has an average rating of “Hold”.

Santen Pharmaceutical Trading Down 4.7%

The stock has a market cap of $3.86 billion and a price-to-earnings ratio of 0.10. The stock has a fifty day simple moving average of $11.16 and a 200-day simple moving average of $10.82.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.